{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:24:26Z","timestamp":1784647466633,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijbiomac.2022.12.090","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T11:12:54Z","timestamp":1671016374000},"page":"974-981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Non-anticoagulant heparin derivatives for COVID-19 treatment"],"prefix":"10.1016","volume":"226","author":[{"given":"Min","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijbiomac.2022.12.090_bb0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.hlpt.2020.10.001","article-title":"The COVID-19 pandemic: global health policy and technology responses in the making","volume":"9","author":"Lee","year":"2020","journal-title":"Health Policy Technol."},{"issue":"10223","key":"10.1016\/j.ijbiomac.2022.12.090_bb0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.ijbiomac.2022.12.090_bb0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cell.2022.01.001","article-title":"Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2","volume":"185","author":"Han","year":"2022","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ijbiomac.2022.12.090_bb0025","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"7861","key":"10.1016\/j.ijbiomac.2022.12.090_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-021-01470-5","article-title":"COVID: treatment trials are still urgent","volume":"594","author":"Rauchman","year":"2021","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.ijbiomac.2022.12.090_bb0035","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 variants-clinical, public health, and vaccine implications","volume":"384","author":"Karim","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.12.090_bb0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaneurol.2022.0154","article-title":"Postmortem assessment of olfactory tissue degeneration and microvasculopathy in patients with COVID-19","volume":"79","author":"Ho","year":"2022","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2022.12.090_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00082-3","article-title":"Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2","volume":"2","author":"Huang","year":"2021","journal-title":"The Lancet Microbe"},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0050","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.3390\/ijms22126574","article-title":"Heparan sulfate proteoglycans in viral infection and treatment: a special focus on SARS-CoV-2","volume":"22","author":"De Pasquale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3201\/eid1003.030683","article-title":"Coronaviridae and SARS-associated coronavirus strain HSR1","volume":"10","author":"Vicenzi","year":"2004","journal-title":"Emerg. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2022.12.090_bb0060","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.12.090_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41421-020-00222-5","article-title":"Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102439","article-title":"Spike-heparan sulfate interactions in SARS-CoV-2 infection","volume":"76","author":"Kearns","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104792","article-title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development","volume":"178","author":"Tang","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.871509","article-title":"Novel insights into the sulfated glucuronic acid-based anti-SARS-CoV-2 mechanism of exopolysaccharides from halophilic archaeon haloarcula hispanica","volume":"10","author":"Xu","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0090","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0095","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01987-20","article-title":"Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives","volume":"95","author":"Tandon","year":"2021","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.12.090_bb0100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1021\/acscentsci.1c00010","article-title":"Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2","volume":"7","author":"Liu","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"13","key":"10.1016\/j.ijbiomac.2022.12.090_bb0105","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1021\/jm030176m","article-title":"Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity","volume":"46","author":"Linhardt","year":"2003","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0110","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1039\/C4NP00076E","article-title":"Chemoenzymatic synthesis of heparan sulfate and heparin","volume":"31","author":"Liu","year":"2014","journal-title":"Nat. Prod. Rep."},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0115","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.drudis.2020.09.011","article-title":"Advances in the preparation and synthesis of heparin and related products","volume":"25","author":"Baytas","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.12.090_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00253-006-0722-x","article-title":"Anticoagulant heparan sulfate: structural specificity and biosynthesis","volume":"74","author":"Liu","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","article-title":"Functions of cell surface heparan sulfate proteoglycans","volume":"68","author":"Bernfield","year":"1999","journal-title":"Annu. Rev. Biochem."},{"issue":"6055","key":"10.1016\/j.ijbiomac.2022.12.090_bb0130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1126\/science.1211605","article-title":"Chemistry. Getting the farm out of pharma for heparin production","volume":"334","author":"Turnbul","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0140","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/microorganisms8121894","article-title":"SARS-CoV-2 inhibition by sulfonated compounds","volume":"8","author":"Gasbarri","year":"2020","journal-title":"Microorganisms"},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.scib.2021.01.010","article-title":"Binding of the SARS-CoV-2 spike protein to glycans","volume":"66","author":"Hao","year":"2021","journal-title":"Sci. Bull. (Beijing)"},{"issue":"2","key":"10.1016\/j.ijbiomac.2022.12.090_bb0150","first-page":"250","article-title":"The thromboplastic action of cephalin","volume":"41","author":"Mclean","year":"1916","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-642-23056-1_8","article-title":"Heparin and heparan sulfate: analyzing structure and microheterogeneity","volume":"207","author":"Shriver","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0160","author":"FDA"},{"issue":"7","key":"10.1016\/j.ijbiomac.2022.12.090_bb0165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/glycob\/cwt016","article-title":"Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature\u2019s longest or most complex carbohydrate chains","volume":"23","author":"DeAngelis","year":"2013","journal-title":"Glycobiology"},{"issue":"23","key":"10.1016\/j.ijbiomac.2022.12.090_bb0170","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa0803200","article-title":"Contaminated heparin associated with adverse clinic events and activation of the contact system","volume":"358","author":"Kishimoto","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.12.090_bb0175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nbt1407","article-title":"Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events","volume":"26","author":"Guerrini","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0185","unstructured":"Guidance for Industry-Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality. Available online: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291390.pdf (accessed on 19 April 2017)."},{"issue":"5","key":"10.1016\/j.ijbiomac.2022.12.090_bb0190","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/jps.23501","article-title":"Structural characterization of pharmaceutical heparins prepared from different animal tissues","volume":"102","author":"Fu","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2022.12.090_bb0195","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3201\/eid1904.121792","article-title":"Hepatitis E virus and porcine-derived heparin","volume":"19","author":"Crossan","year":"2013","journal-title":"Emerg. Infect. Dis."},{"issue":"14","key":"10.1016\/j.ijbiomac.2022.12.090_bb0200","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.1021\/acs.chemrev.6b00010","article-title":"Chemical synthesis of glycosaminoglycans","volume":"116","author":"Mende","year":"2016","journal-title":"Chem. Rev."},{"issue":"11","key":"10.1016\/j.ijbiomac.2022.12.090_bb0205","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1002\/tcr.202100173","article-title":"Developments in the chemical synthesis of heparin and heparan sulfate","volume":"21","author":"Pongener","year":"2021","journal-title":"Chem. Rec."},{"issue":"6055","key":"10.1016\/j.ijbiomac.2022.12.090_bb0210","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.1207478","article-title":"Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins","volume":"334","author":"Xu","year":"2011","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ijbiomac.2022.12.090_bb0215","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1039\/C7SC03541A","article-title":"Chemoenzymatic synthesis of heparan sulfate and heparin oligosaccharides and NMR analysis: paving the way to a diverse library for glycobiologists","volume":"8","author":"Zhang","year":"2017","journal-title":"Chem. Sci."},{"issue":"39","key":"10.1016\/j.ijbiomac.2022.12.090_bb0220","doi-asserted-by":"crossref","first-page":"12998","DOI":"10.1021\/ja8026345","article-title":"Solution structures of chemoenzymatically synthesized heparin and its precursors","volume":"130","author":"Zhang","year":"2008","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.12.090_bb0225","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/bit.22898","article-title":"Coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor","volume":"107","author":"Wang","year":"2010","journal-title":"Biotechnol. Bioeng."},{"issue":"5","key":"10.1016\/j.ijbiomac.2022.12.090_bb0230","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-2001-17954","article-title":"Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide","volume":"27","author":"Naggi","year":"2001","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0235","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pharmthera.2009.05.001","article-title":"Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides","volume":"123","author":"Rusnati","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0240","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/1521-3773(20020201)41:3<390::AID-ANIE390>3.0.CO;2-B","article-title":"Heparin-protein interactions","volume":"41","author":"Capila","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"4","key":"10.1016\/j.ijbiomac.2022.12.090_bb0245","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.xphs.2016.11.023","article-title":"Structural analysis of heparin-derived 3-O-sulfated tetrasaccharides: antithrombin binding site variants","volume":"106","author":"Chen","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0250","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/13543784.2014.866092","article-title":"Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality?","volume":"23","author":"Madhur","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102969","article-title":"Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients","volume":"59","author":"Buijsers","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575047","article-title":"Increased plasma heparanase activity in COVID-19 patients","volume":"11","author":"Buijsers","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0265","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-3-642-23056-1_12","article-title":"Non-anticoagulant effects of heparin: an overview","volume":"207","author":"Lever","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0270","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","article-title":"Old and new applications of non-anticoagulant heparin","volume":"212","author":"Cassinelli","year":"2016","journal-title":"Int. J. Cardio."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0275","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/978-3-030-34521-1_20","article-title":"Non-anticoagulant heparins as heparanase inhibitors","volume":"1221","author":"Cassinelli","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2022.12.090_bb0280","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1021\/acsinfecdis.9b00425","article-title":"Non-anticoagulant heparin as a pre-exposure prophylaxis prevents Lyme disease infection","volume":"6","author":"Lin","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.12.090_bb0285","doi-asserted-by":"crossref","first-page":"C97","DOI":"10.1152\/ajpcell.00009.2010","article-title":"Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands","volume":"299","author":"Rao","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.12.090_bb0290","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0022-3565(24)36816-8","article-title":"Selective O-desulfation produces non-anticoagulant heparin that retains pharmacological activity in the lung","volume":"282","author":"Fryer","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116824","article-title":"A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions","volume":"249","author":"Ji","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"27","key":"10.1016\/j.ijbiomac.2022.12.090_bb0300","doi-asserted-by":"crossref","first-page":"23671","DOI":"10.18632\/oncotarget.4409","article-title":"Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis","volume":"6","author":"Duckworth","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.carbpol.2015.08.041","article-title":"Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization","volume":"135","author":"Achour","year":"2016","journal-title":"Carbohydr. Polym."},{"issue":"11","key":"10.1016\/j.ijbiomac.2022.12.090_bb0310","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.bjc.6600307","article-title":"Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung","volume":"86","author":"Ono","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2022.12.090_bb0315","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.carbpol.2016.09.032","article-title":"Structural features of heparanase-inhibiting non-anticoagulant heparin derivative roneparstat","volume":"156","author":"Alekseeva","year":"2017","journal-title":"Carbohydr. Polym."},{"issue":"6","key":"10.1016\/j.ijbiomac.2022.12.090_bb0320","first-page":"816","article-title":"Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin","volume":"96","author":"Mousa","year":"2006","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.ijbiomac.2022.12.090_bb0325","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1073\/pnas.77.11.6551","article-title":"Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin","volume":"77","author":"Lindahl","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022029920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022029920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:56:25Z","timestamp":1758880585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022029920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":64,"alternative-id":["S0141813022029920"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.12.090","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-anticoagulant heparin derivatives for COVID-19 treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.12.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}